PLMA_1170x120_10-8-21

U.S. pharmaceutical supply chain

U.S. pharmaceutical supply chain requires overhaul says business group expert forum

U.S. pharmaceutical supply chain requires overhaul says business group expert forum

WASHINGTON – The U.S. pharmaceutical supply chain must be remodeled to address long-standing conflicts and achieve a delivery model marked by transparency, affordability and access, a multistakeholder working committee created by Business Group on Health recommended today to industry leaders and government regulators. The committee, composed of employers, health plans, pharmacy benefit managers, pharmaceutical manufacturers,

HDA, NACDS CEOs: Rx importation not worth risk

HDA, NACDS CEOs: Rx importation not worth risk

Efforts to promote the importation of prescription drugs — seen by some as one way to mitigate the escalating cost of medications — could compromise the safety of the U.S. pharmaceutical supply chain, according to HDA’s John Gray and NACDS’ Steve Anderson. In a blog post on Monday for the policy journal The Hill, Gray,